Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P W Collins

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patientsP W Collins, D V K Quon, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 7, 2005
A framework for genetic service provision for haemophilia and other inherited bleeding disordersC A Ludlam, K J Pasi, P Bolton-Maggs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 25, 2006
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conferenceE Berntorp, A Shapiro, J Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 28, 2015
Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experimentJ Lock, E W de Bekker-Grob, G Urhan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AM D Tarantino, P W Collins, C R M Hay, et al.
Journal of Medicinal Chemistry|May 23, 1997
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agentsI K Khanna, R M Weier, Y Yu, et al.
Journal of Medicinal Chemistry|August 24, 2000
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agentsI K Khanna, Y Yu, R M Huff, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 1, 2018
Perioperative replacement therapy in haemophilia B: An appeal to "B" more preciseH C A M Hazendonk, T Preijers, R Liesner, et al.
Journal of Thrombosis and Haemostasis : JTH|November 6, 2018
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgeryT Preijers, H C A M Hazendonk, R Liesner, et al.
Journal of Medicinal Chemistry|April 25, 1997
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)T D Penning, J J Talley, S R Bertenshaw, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 24, 2017
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patientsP W Collins, D V K Quon, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 7, 2005
A framework for genetic service provision for haemophilia and other inherited bleeding disordersC A Ludlam, K J Pasi, P Bolton-Maggs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 25, 2006
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conferenceE Berntorp, A Shapiro, J Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 28, 2015
Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experimentJ Lock, E W de Bekker-Grob, G Urhan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2004
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia AM D Tarantino, P W Collins, C R M Hay, et al.
Journal of Medicinal Chemistry|May 23, 1997
1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agentsI K Khanna, R M Weier, Y Yu, et al.
Journal of Medicinal Chemistry|August 24, 2000
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agentsI K Khanna, Y Yu, R M Huff, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 1, 2018
Perioperative replacement therapy in haemophilia B: An appeal to "B" more preciseH C A M Hazendonk, T Preijers, R Liesner, et al.
Journal of Thrombosis and Haemostasis : JTH|November 6, 2018
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgeryT Preijers, H C A M Hazendonk, R Liesner, et al.
Journal of Medicinal Chemistry|April 25, 1997
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)T D Penning, J J Talley, S R Bertenshaw, et al.
Pageof 16